
    
      Randomized, double-blind, placebo-controlled, parallel-group, single-center phase 2 pilot
      study.The experimental group will receive an intravenous titration of morphine followed by a
      subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined
      protocol. The control group will receive placebo NaCl 0.9% administered according to the same
      protocol as the experimental arm Patients will be randomized 1:1 between low-dose titrated
      morphine (experimental group) and placebo (control group). The other treatments will be
      similar in both groups, according to the protocol and the recommendations.

      Severe dyspnea will be assessed for regularly Patients will be followed for 48 hours: 24-hour
      treatment duration, evaluation of primary endpoint for first 24 hours, collection of adverse
      events for 48 hours.
    
  